Contract 75N94025F00001
Health Decisions, Inc. · Department Of Health And Human Services · June 30, 2025
Health Decisions, Inc. was awarded a federal contract by Department Of Health And Human Services (National Institutes Of Health) on June 30, 2025 for $8.83 million of work in research and development in the physical, engineering, and life sciences (except nanotechnology and biotechnology). Performance is in Durham, NC. This is a task or delivery order issued under parent IDIQ 75N94019D00004. It was awarded under a small business set-aside. The contract has been modified 47 times since the base award It uses cost-plus contract pricing. The most recent modification was on February 23, 2026.
Contract details
- PIID
- 75N94025F00001
- Parent IDIQ
- 75N94019D00004
- Award type
- Delivery Order
- Pricing
- Cost Plus Fixed Fee
- Set-aside
- Women Owned Small Business
- Competition
- Full And Open Competition After Exclusion Of Sources
- NAICS
- 541715 · Research And Development In The Physical, Engineering, And Life Sciences (Except Nanotechnology And Biotechnology)
- Product / service
- Health R&D Services; Health Care Services; Applied Research
- Place of performance
- Durham, NC
- First action
- June 30, 2025
- Latest action
- February 23, 2026
Description
NICHD: R&D: COORDINATION, MONITORING, FOLLOW-UP, EVALUATION, AND COMPLETION OF A CLINICAL TRIAL OF NESTORONE TESTOSTERONE GEL FOR MALE CONTRACEPTION: NON-SEVERABLE
Modification timeline
-
February 23, 2026Mod P00001 · Funding Only Action$1.06M
-
January 30, 2026Mod P00001 · Other Administrative ActionNICHD: R&D: A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION: SEVERABLE$143.2K
-
January 30, 2026Mod P00001 · Other Administrative ActionNICHD: SERVICE: CCTN LB PHASE 2B CLINICAL TRIAL: NON-SEVERABLE$94.1K
-
January 29, 2026Mod P00001 · Other Administrative ActionNICHD: SERVICE: CCTN LB PHASE 2B CLINICAL TRIAL: NON-SEVERABLE$100.0K
-
January 28, 2026Mod P00001 · Other Administrative ActionNICHD: R&D: TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS (PK), PHARMACODYNAMIC (PD) EFFECTS, SAFETY, AND CONTRACEPTIVE EFFICACY OF LEVONORGESTREL BUTANOATE (LB) FORMULATED AS A LONG-A…$97.8K
-
January 28, 2026Mod P00001 · Other Administrative ActionNICHD: SERVICE: CCTN LB PHASE 2B CLINICAL TRIAL: NON-SEVERABLE$86.6K
-
January 26, 2026Mod P00001 · Other Administrative ActionNICHD: R&D: A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION: NON-SEVERABLE$99.9K
-
January 23, 2026Mod P00002 · Funding Only ActionNICHD: R&D: BEST PHARMACEUTICALS FOR CHILDREN ACT (BPCA) PEDIATRIC TRIALS NETWORK (PTN): CORE FUNCTION ACTIVITIES: SEVERABLE$2.42M
-
January 21, 2026Mod P00003 · Other Administrative ActionNICHD: SERVICE: ADMINISTRATIVE TASK ORDER: SEVERABLE$309.0K
-
December 23, 2025Mod P00001 · Other Administrative ActionNICHD: R&D: A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION: NON-SEVERABLE$24.9K
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Leidos Biomedical Research Inc | Department Of Health And Human Services | April 1, 2026 | $20.43M |
| Leidos Biomedical Research Inc | Department Of Health And Human Services | April 1, 2026 | $9.22M |
| Leidos Biomedical Research Inc | Department Of Health And Human Services | April 1, 2026 | $8.00M |
| Leidos Biomedical Research Inc | Department Of Health And Human Services | April 1, 2026 | $327.13M |
| The Emmes Company, Llc | Department Of Health And Human Services | April 1, 2026 | $771.5K |
| Lovelace Biomedical Research Institute | Department Of Health And Human Services | April 1, 2026 | $680.2K |
Top contractors in NAICS 541715
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Fluor Marine Propulsion, Llc | 2 | $2.75B |
| 2 | California Institute Of Technology | 240 | $979.40M |
| 3 | The Johns Hopkins University Applied Physics Laboratory Llc | 204 | $482.74M |
| 4 | Lockheed Martin Corporation | 4 | $461.91M |
| 5 | Lockheed Martin Corp | 9 | $317.27M |
| 6 | The Aerospace Corporation | 85 | $308.18M |
| 7 | Fermi Forward Discovery Group, Llc | 1 | $289.92M |
| 8 | Lockheed Martin Corp | 7 | $285.45M |
| 9 | Amentum Technology, Inc. | 4 | $253.24M |
| 10 | The Mitre Corporation | 50 | $222.51M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75N94025F00001?
Contract 75N94025F00001 is a federal contract awarded to Health Decisions, Inc. by Department Of Health And Human Services on June 30, 2025 for $8.83 million of work classified under RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY). It has been modified 47 times since the base award.
Who won contract 75N94025F00001?
Health Decisions, Inc. won contract 75N94025F00001 from Department Of Health And Human Services.
How much is contract 75N94025F00001 worth?
Contract 75N94025F00001 has obligated $8.83 million to date.